Announced details
Advanced or recurrent cervical cancer, regenerative medicine and gene therapy, and TIL therapy
We have a track record of contract manufacturing TIL products used in advanced medical care, but the quantity is Not disclosed.
We submitted a proposal under AMED's public call for proposals, and the proposal was selected. The final grant amount is scheduled to be determined in AMED's notice of grant award.
Japan Agency for Medical Research and Development (AMED). Other information, including its location, representative, capital, year of establishment and business activities, is Not disclosed.
No impact on consolidated results for the fiscal year ending March 2027
The company does not address Contract Value / Offering price.
Japan Agency for Medical Research and Development (AMED)'s public call for proposals and links provided by AMED
| Item | Details |
|---|---|
| Names of Products / Services Covered | TIL regenerative medical product for advanced or recurrent cervical cancer |
| Counterparty | Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | Japan Agency for Medical Research and Development (AMED). Other information, including its location, representative, capital, year of establishment and business activities, is Not disclosed. |
| Relationship with the Company | We submitted a proposal under AMED's public call for proposals, and the proposal was selected. The final grant amount is scheduled to be determined in AMED's notice of grant award. |
| Applicable area | Advanced or recurrent cervical cancer, regenerative medicine and gene therapy, and TIL therapy |
| Usage history | We have a track record of contract manufacturing TIL products used in advanced medical care, but the quantity is Not disclosed. |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending March 2027 |
| Source | Japan Agency for Medical Research and Development (AMED)'s public call for proposals and links provided by AMED |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Our proposal under AMED's public call for proposals was selected.